Gene therapy is a process to treat or prevent disease replacing the mutated genes with healthy genes. This replacement allows the cells for the production of useful proteins. It can also change the way genes are generated. This enables under- or overactive genes to operate properly. Gene therapy can be used for expressing entirely foreign genes in cells that alter their function or survival. During cancer treatment, the genes are replaced for fighting against carcinogenic tumor cells. Cancer gene therapy inserts therapeutic DNA into the patient for the treatment of cancer. It is considered to be an effective treatment for cancer as it causes minimum side effects with maximum efficacy.
The factors that are contributing significantly to the growth of global cancer gene therapy market includes rising pool of population with cancer patients coupled with increasing geriatric population base. Globally there is rise in the cancer patients each year. According to the WHO cancer is considered to be the second leading cause of deaths in the year 2015. It is also estimated that that 1 death out of 6 deaths is caused by cancer. Rise in R&D activities owing to the extensive funding in the field of cancer gene therapy is another major factor for the prevalence of cancer gene therapy. However, high cost of the treatment is a factor that has negative impact on the growth of the market.
The cancer gene therapy market can be segmented on the basis of therapy and end users. Based on the therapy, the cancer gene therapy market is bifurcated as gene transfer immunotherapy, oncolytic virotherapy and gene induced immunotherapy. The gene induced immunotherapy is further segmented as delivery of cytokines gene and delivery of tumor antigen gene. On the basis of end users, the global cancer gene therapy market is diversified as hospitals, research institutes and biotech companies.
The global cancer gene therapy market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The regions analyzed in the report involve North America, Europe, APAC and Rest of the World. The North America is expected to be dominating in the cancer gene therapy market owing to the presence of high quality healthcare infrastructure. In addition, presence of large pool of cancer patients and aging population in the region is another factor responsible for the regional growth. Europe is another significant market and holds a considerable market share in the global cancer gene therapy market.
Some of the players operating in the global cancer gene therapy market are Merck & Co., Inc., Bluebird bio Inc., Celgene Corporation and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For an instance, Celgene Corporation in July 2015 entered into a strategic immuno-oncology collaboration with BeiGene, Ltd. for advancing PD-1 Inhibitor program for solid tumor cancers.
The market study of cancer gene therapy market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as American College of Rheumatology, American Association for Clinical Chemistry (AACC), and American Autoimmune Related Diseases Association (AARDA), among others.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for drug manufacturers, healthcare provider, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
Global Cancer gene therapy market is segmented on the basis of regional outlook and following segments:
Global Cancer gene therapy Market Research and Analysis, By Therapy
Global Cancer gene therapy Market Research and Analysis, By End Users
Global Cancer gene therapy Market Research and Analysis, By Region
The Report covers:
Comprehensive research methodology of global cancer gene therapy
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global cancer gene therapy market.
Insights about market determinants which are stimulating the global cancer gene therapy market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.